Hepatology & Liver Transplantation Trials
- A UK Collaborative Study to Determine the Genetic Basis of Primary Sclerosing Cholangitis (UK-PSC)
- Prospective Cohort for Early Detection of Liver Cancer
- Investigation of the Genetic and Molecular Pathogenesis of Primary Biliary Cirrhosis
- The detection of Small Early Liver cancer with Natural history follow up (SELINA)
- The Wilson’s Disease Registry
- A PROspective randomised double-blind parallel group placebo-controlled multicentre trial of faecal MIcrobiota tranSplantation to improve the primary outcomE (first hospitalisation due to infection) in patients with cirrhosis over 24 months.
- Alcohol and Liver Health: A prospective database of individuals with all stages of alcohol related liver disease (ArLD)
- Real world implementation of AlcoChange: a smartphone digital therapeutic to improve outcomes from alcohol-related liver disease
- The United Kingdom Autoimmune Hepatitis Cohort (UK-AIH): a multi-centre platform for research and translational medicine
- WALDO – Worldwide Alcoholic Liver Disease Outcomes study
- EON – Experience and Outcomes in Non-alcoholic fatty liver disease (NAFLD).
- Primary Antibiotic prophylaxis using co trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis (ASEPTIC)
- Steroid Hormones, Liver Disease and Hepatocellular Carcinoma (Steroids and HCC)
- A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects with Primary Sclerosing Cholangitis (Chemomab and SPRING)
- Liver transplantation in patients with CirrHosis and severe Acute-on-Chronic Liver Failure (ACLF): iNdications and outComEs (CHANCE) Study on behalf of the EASL-CLIF Consortium
- The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis (ESSENCE)
- WAFT-C Warfarin Anticoagulation for liver fibrosis in patients transplanted for HCV
- LEAN Liraglutides Action and efficacy in NASH
- ELUCIDATE ELF to Uncover Cirrhosis as an indication for Diagnosis and action for treatable events
- ELUCIDATE patients experience
- GILEAD A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection
- ATTAIN(Retreatment of null and partial responders with TMC435) A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null or partial responders to prior PegIFNα and ribavirin therapy
- DILIGEN Pharmacogenetics of drug induced liver injury
- STOPAH. Steriods or Pentoxifylline for Alcoholic Hepatitis
- Drug Utilization of DAAs and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Patients
- Hepatitis C Rimantadine and Antiviral Combination Therapy – “HepRiACT” trial
- UK-PBC Nested Cohort Study
- Albumin to prevent infection in chronic liver failure (ATTIRE)
- Phase 2 EDP-305 in patients with primary biliary cholangitis
- AURORA
- ISAIAH
- PROSPER (Prospective Real World Outcomes Study of Hepatic Encephalopathy Patients’ Experience of Rifaximin)
- A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure
- GILEAD – A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects with Chronic HCV Infection who have received a Liver Transplant
- TACE-2 Research trial evaluating sorafenib in combination with chemoembolization in patients with unresectable advanced Hepatocellular Carcinoma
